PD-L1 expression was observed in 10/30 cases (33.3%) (range of PD-L1 expression 3–20%), of which 3/14 (21.4%) were primary melanomas and 7/16 (43.7%) were unmatched in-transit melanoma metastases. This evidence concerns the gene CD274 and melanoma.